Khimki, Russia

Oleg D Mitkin

This inventor holds 1 USPTO granted patent. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Oleg D Mitkin. Retrieved from https://idiyas.com/inventor/oleg-d-mitkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oleg D. Mitkin: Inventor in Medicinal Chemistry

Introduction

Oleg D. Mitkin is an inventor associated with Khimki, Russia. His patent work concerns compounds intended to inhibit specific kinases, targets relevant to the treatment of certain diseases and disorders.

Latest Patents

Mitkin is named on 1 patent: “Substituted 1H-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof.” The invention describes inhibitors of hematopoietic progenitor kinase 1 (HPK1) and FMS-like tyrosine kinase 3 (FLT3), and their potential use in treating diseases and disorders modulated by these targets. The patent presents compounds having Formula I, along with methods for their preparation and use.

Career Highlights

The available information highlights Mitkin’s contribution to research and development involving kinase inhibitors. His patent connects medicinal chemistry with the investigation of potential therapeutic compounds.

Collaborations

Mitkin’s listed coworkers include Ruben Abagyan and Vladislav Zenonovich Parchinsky. Their association reflects collaborative work related to the patented compounds and their preparation and use.

Conclusion

Oleg D. Mitkin’s patent record centers on substituted pyrazoloquinolines developed as potential HPK1 and FLT3 inhibitors, illustrating his contribution to therapeutic innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…